Rupatadine does not potentiate the CNS depressant effects of lorazepam: Randomized, double-blind, crossover, repeated dose, placebo-controlled study

British Journal of Clinical Pharmacology

Volumn 69, Issue 6, 2010, Pages 663-674

  García Gea, Consuelo ^a,b,c   Ballester, Maria Rosa ^a,b,c   Martínez, Juan ^a,b,c   Antonijoan, Rosa Maria ^a,b,c   Donado, Esther ^d   Izquierdo, Iñaki ^d   Barbanoj, Manuel José ^a,b,c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d Grupo Uriach   (Spain)

Author keywords

CNS effects; Healthy volunteers; Interaction; Lorazepam; Rupatadine

Indexed keywords

LORAZEPAM; PLACEBO; RUPATADINE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DEPRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SEDATION; SINGLE DRUG DOSE; STEADY STATE; VISUAL ANALOG SCALE;

ADULT; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CROSS-OVER STUDIES; CYPROHEPTADINE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORAZEPAM; MALE; PSYCHOMOTOR PERFORMANCE;

EID: 77952048122     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03648.x     Document Type: Article

References (51)

1. Amstrong S, Cozza K, Benedek D. Med-psych drug-drug interactions update. Psychosomatics 2002 43 : 245 254. (Pubitemid 34522538)
2. Amstrong S, Cozza K. Med-psych drug-drug interactions update: antihistamines. Psychosomatics 2003 44 : 430 434. (Pubitemid 37071933)
3. Starmer G. Antihistamines and highway safety. Accid Anal Prev 1985 17 : 311 317.
4. Hindmarch I. CNS effects of antihistamines: is there a third generation of non-sedative drugs? Clin Exp Allergy Rev 2002 2 : 26 31. (Pubitemid 35300630)
5. Bousquet J, Cauwenberge P, Khaltaev N, Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl. 5) S147 S334.
6. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, Simons FE, Spangler DL, Szefler SJ, Terndrup TE, Waldman SA, Weiler J, Wong DF. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003 111 : S835 S42. (Pubitemid 36570885)
7. Shamsi X, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol Clin Exp 2000 15 : S3 S30.
8. McDonald K, Trick L, Boyle J. Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol Clin Exp 2008 23 : 555 570.
9. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 1997 280 : 114 121. (Pubitemid 27171394)
10. Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert Opin Pharmacother 2002 7 : 1989 2001. (Pubitemid 44489371)
11. Barbanoj MJ, García-Gea C, Morte A, Izquierdo I, Pérez I, Jané F. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagoist, at different doses in healthy volunteers. Neuropsychobiology 2004 50 : 311 321. (Pubitemid 39482671)
12. Barbanoj MJ, García-Gea C, Antonijoan R, Izquierdo I, Donado E, Pérez I, Solans A, Jané F. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol 2006 21 : 13 26. (Pubitemid 43192472)
13. Parrot AC. Performance tests in human psychopharmacology (1): test reliability and standardization. Hum Psychopharmacol 1991 6 : 1 9.
14. Parrot AC. Performance tests in human psychopharmacology (2): content validity, criterion validity, and face validity. Hum Psychopharmacol 1991 6 : 91 8.
15. Parrot AC. Performance tests in human psychopharmacology (3): construct validity and test interpretation. Hum Psychopharmacol 1991 6 : 197 207.
16. Lorenzo JL, Barbanoj MJ. Variability of sleep parameters across multiple laboratory sessions in healthy young subjects: the 'very first night effect'. Psychophysiology 2002 39 : 409 413.
17. Solans A, Izquierdo I, Donado E, Antonijoan R, Peña J, Nadal T, Carbó ML, Merlos M, Barbanoj M. Pharmacokinetic and safety profile of rupatadine when co-administered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. Clin Ther 2008 30 : 1639 1650.
18. Patat A, Perault MC, Vandel B, Ulliac N, Zieleniuk I, Rosenzweig P. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers. Br J Clin Pharmacol 1995 39 : 31 8.
19. File SE, Bond AJ. Impaired performance and sedation after a single dose of lorazepam. Psychopharmacology (Berl) 1979 66 : 309 313.
20. Preston GC, Broks P, Traub M, Ward C, Poppleton P, Stahl SM. Effects of lorazepam on memory, attention and sedation in man. Psychopharmacology (Berl) 1988 95 : 208 215.
21. Lister RG, File SE. The nature of lorazepam-induced amnesia. Psychopharmacology (Berl) 1984 83 : 183 187.
22. Patat A, Foulhoux P. Effect on postural sway of various benzodiazepine tranquillizers. Br J Clin Pharmacol 1985 20 : 9 16. (Pubitemid 15229450)
23. Curran HV, Scjowy W, Lader M. Differential amnesic properties of benzodiazepines: a dose-response comparison of two drugs with similar elimination half-lives. Psychopharmacology (Berl) 1987 92 : 358 364. (Pubitemid 17100485)
24. Block RI, Berchou R. Alprazolam and lorazepam effects on memory acquisition and retrieval processes. Pharmacol Biochem Behav 1984 20 : 233 241. (Pubitemid 14167970)
25. Griffiths RR, Evans SM, Guarino JJ, Roache JD, Furman WR, Liebson I, Schwam EM. Intravenous flumazenil following acute and repeated exposure to lorazepam in healthy volunteers: antagonism and precipitated withdrawal. J Pharmacol Exp Ther 1993 265 : 1163 1174. (Pubitemid 23321015)
26. 1 receptor antagonists: safety issues. Ann Allergy Asthma Immunol 1999 83 : 481 488.
27. -receptor antagonists. Eur J Clin Pharmacol 1985 28 : 523 529. (Pubitemid 15030777)
28. Bhatti JZ, Hindmarch I. The effects of terfenadine with and without alcohol on an aspect of car driving performance. Clin Exp Allergy 1989 19 : 609 611. (Pubitemid 20006148)
29. Betts TA, Edson AE, Furlong PL. The effect of single dose of 120 mg and 240 mg of terfenadine on driving and other measures of psychomotor performance including visual evoked responses. Ann Allergy 1991 66 : 98.
30. Riedel WJ, Van Veggel L, O'Halon JF. Cetirizine 10 and 20 mg impair psychomotor performance. Clin Exp Allergy 1990 20 : 97.
31. Bradley CM, Nicholson AN. Studies on the central effects of the H1-antagonist, loratadine. Eur J Clin Pharmacol 1987 32 : 419 421. (Pubitemid 17077191)
32. Percharder JC, Beudin P, Eschalier A, Trolese JF, Rihoux JP. A comparison of central and peripheral effects of cetirizine and loratadine. J Int Med Res 1991 19 : 285 295.
33. García-Gea C, Martínez-Colomer J, Antonijoan MR, Valiente R, Barbanoj MJ. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine. A dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Phychopharmacol 2008 28 : 675 685.
34. Pecharder JC, Vernay D, Trolese JF, Bloom M, Dupont P, Rihoux JP. Comparison of the central and peripheral effects of cetirizine and terfenadine. Eur J Clin Pharmacol 1988 35 : 255 259.
35. Ramaekers JG, Uiterwijk NMC, O'Halon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance and EEG during driving. Eur J Clin Pharmacol 1992 42 : 363 369.
36. Volkerts ER, Van Willenburg AP, Van Laar MW, Maes RAA. Does cetirizine belong to the new generation of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric test performace and daytime sleepiness. Hum Psychopharmacol 1992 7 : 227 238.
37. Moser L, Hüther KJ, Koch-Weser J, Lundt PV. Effects of terfenadine and diphenhydramine alone or in combination with diazepam or alcohol on psychomotor performance and subjective feelings. Eur J Clin Pharmacol 1978 14 : 417 423. (Pubitemid 9060904)
38. Mattila MJ, Mattila M, Konno K. Acute and subacute actions on human performance and interactions with diazepam of temelastine (SK&F93944) and diphenhydramine. Eur J Clin Pharmacol 1986 31 : 291 298. (Pubitemid 17021629)
39. Mattila MJ, Aranko K, Kuitunen T. Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine. Br J Clin Pharmacol 1993 35 : 272 277. (Pubitemid 23074052)
40. Ghoneim MM, Hinrichs JV, Mewaldt SP. Dose-response analysis of the behavioural effect of diazepam I: learning and memory. Psychopharmacology (Berl) 1984 82 : 291 295.
41. Ghoneim MM, Mewaldt SP, Hinrichs JV. Dose-response analysis of the behavioural effect of diazepam II: psychomotor performance cognition and mood. Psychopharmacology (Berl) 1984 82 : 296 300.
42. Patat A, Klein MJ, Hucher M, Granier J. Acute effects of amitriptyline on human performance and interactions with diazepam. Eur J Clin Pharmacol 1988 35 : 585 592. (Pubitemid 19000275)
43. Saletu B, Grünberger J, Anderer P, Barbanoj MJ. Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: electroencephalographic brain mapping and safety evaluation. Curr Ther Res 1988 44 : 909 937. (Pubitemid 19023969)
44. Grünberger J, Saletu B, Linzmayer L, Barbanoj MJ. Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: psychometric and psychophysiological data. Curr Ther Res 1988 44 : 938 965. (Pubitemid 19023970)
45. Cole JO, Kando JC. Adverse behavioural events reported in patients taking alprazolam and other benzodiazepines. J Clin Psychiatry 1993 54 (Suppl. 49-61 62 3.
46. Vermeeren A, Ramaekers G, O'Halon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 2002 16 : 57 64. (Pubitemid 34273074)
47. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980 10 : 189 209. (Pubitemid 10049156)
48. Hindmarch I. Psychometric of drug effects in volunteers and patients. Pharm Med 1988 3 : 135 142.
49. Barbanoj MJ, Lorenzo JL, Clos S, García-Gea C, Jané F. Proof of safety of drugs: focus on vigilance. Methods Find Exp Clin Pharmacol 2002 24 (Suppl. C 51 64. (Pubitemid 35447383)
50. Cohen AF, Posner J, Ashby L, Smith R, Peck AW. A comparison of methods for assessing the sedative effects of diphenhydramine on skill related to car driving. Eur J Clin Pharmacol 1984 27 : 477 482. (Pubitemid 15217765)
51. Vuurman E, Theunissen E, van Oers A, Van Leeuwen C, Jolles J. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol Clin Exp 2007 22 : 289 297. (Pubitemid 47180390)